Skip to main content

Advertisement

Table 1 Association between clinical markers and Menacalc expression availability in the TMA cohort (n = 888)

From: Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Characteristic Menacalc score available Menacalc score unavailable P-valued
  (n = 403a) (n = 483)  
  Number % Number %  
Menopausal status
  pre 151 37.5 141 29.2 0.0330
  peri 19 4.7 25 5.2  
  post 233 57.8 317 65.6  
Tumor Size       
  <0.5 cm 5 1.2 11 2.3 0.0198
  0.5 to < 1.0 cm 41 10.2 81 16.8  
  1.0 to < 2.0 cm 174 43.2 199 41.2  
  2 to 5 cm 164 40.7 179 37.0  
  >5 cm 19 4.7 13 2.7  
Estrogen receptor
  Positive 239 59.3 307 63.6 0.2806
  Negative/Equivocal 104 25.8 103 21.3  
  NDb 60 14.9 73 15.1  
Progesterone receptor
  Positive 215 53.3 280 58.0 0.2699
  Negative/Equivocal 128 31.8 130 26.9  
  NDb 60 14.9 73 15.1  
Histological grade
  1c 99 24.6 174 36.0 <0.0001
  2 147 36.4 152 31.5  
  3 132 32.8 100 20.7  
  NDb 25 6.2 57 11.8  
Adjuvant treatment
  Hormonal 169 41.9 205 42.4 0.0571
  Chemotherapy 78 19.4 64 13.3  
  Both 14 3.5 14 2.9  
  None 142 35.2 200 41.4  
Lymphatic Invasion
  Yes 70 17.4 47 9.7 0.0008
  No 332 82.6 436 90.3  
  Missing 1e   0   
Age group  
  <50 yrs 157 39.0 149 30.9 0.0115
  ≥50 yrs 246 61.0 334 69.1  
  1. awithout patients with most baseline unavailable data
  2. bUnknown, not done or missing
  3. cIncludes mucinous, lobular and tubular subtypes
  4. dChi-square test
  5. (ewithout missing category)